{"id":849,"date":"2019-03-14T14:26:09","date_gmt":"2019-03-14T13:26:09","guid":{"rendered":"https:\/\/sites.centri.univr.it\/invite\/?page_id=849"},"modified":"2019-03-14T16:34:46","modified_gmt":"2019-03-14T15:34:46","slug":"mathieu-repellin","status":"publish","type":"page","link":"https:\/\/sites.centri.univr.it\/invite\/the-invite-phd-candidates\/mathieu-repellin\/","title":{"rendered":"Mathieu Repellin"},"content":{"rendered":"\n
\"Mathieu
Mathieu Repellin<\/figcaption><\/figure><\/div>\n\n\n\n

Biosketch<\/h2>\n\n\n\n

My name is\nMathieu Repellin and I\u2019m doing my PhD in Nanoscience and Advanced Technologies\nin the framework of the European project INVITE. I\u2019m 24 years old, I\u2019m French\nand I come from Grenoble, a city in the east of France, near to the Alps. I\nperformed my studies in chemistry and after 3 years of general chemistry, I\ndecided to focus my studies, through a Master, in formulation, which is the\nstudy of the composition of a mixture in order to obtain a product with\nspecific end properties. During this Master, I had the opportunity to carry out\na one-year work-study internship (8 months of work and 4 months of courses) in\na French institute (CEA) on nanomedicine, field for which I developed quickly a\nkeen great interest. Through this experience, my strong interest in research\nwas increased and took me to consider the opportunity of carrying out a\ndoctorate in this field. <\/p>\n\n\n\n

Project<\/h2>\n\n\n

PhD candidate<\/strong>: Mathieu Repellin
Supervisor<\/strong>: Manuela Malatesta
Title<\/strong>: Nanoparticle-mediated drug delivery as an innovative strategy for treating myotonic dystrophy (NanoSTreaM)
PhD Programme<\/strong>: Nanosciences and Advanced Technologies<\/p>\n\n\n

The subject of my research project is to design and develop biocompatible nanocarriers loaded with small molecules (as oligonucleotides) for the treatment of Myotonic Dystrophy type 1, which is a genetic disorder mainly affecting muscles with disabling effects for the patient and possibly premature death. Currently, no therapeutic strategies are available but molecules with promising experimental results are established. However, these molecules have no therapeutic application due to their toxicity and\/or degradability. Thus, this research project aims at developing a novel experimental therapeutic strategy using biocompatible nanocarriers able to encapsulate the active agents to the cells, in order to provide better treatment procedure to patients by guaranteeing the protection of the active encapsulated agent and allowing improved specificity and tolerability of the administered formulation. <\/p>\n","protected":false},"excerpt":{"rendered":"

Biosketch My name is Mathieu Repellin and I\u2019m doing my PhD in Nanoscience and Advanced Technologies in the framework of the European project INVITE. I\u2019m 24 years old, I\u2019m French and I come from Grenoble, a city in the east of France, near to the Alps. I performed my studies in chemistry and after 3 years of general chemistry, I decided to focus my studies,… <\/p>\n

Read More<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":807,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"pageleftnav.php","meta":{"footnotes":""},"yoast_head":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n